Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Age Related Macular Degeneration (ARMD): full-pipeline trial registry
1 of 2 indexed Age Related Macular Degeneration (ARMD) trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Age Related Macular Degeneration (ARMD): 2 US clinical trials tracked, 1 recruiting.
Age Related Macular Degeneration (ARMD) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Stealth BioTherapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition age-related-macular-degeneration-armd
OPEN 1 | RECR 50% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Age Related Macular Degeneration (ARMD) lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Age Related Macular Degeneration (ARMD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Age Related Macular Degeneration (ARMD) is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
Aptabio Therapeutics
NCT07330674
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Stealth BioTherapeutics
NCT06373731
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Age Related Macular Degeneration (ARMD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Age Related Macular Degeneration (ARMD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Age Related Macular Degeneration (ARMD) page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Age Related Macular Degeneration (ARMD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Stealth BioTherapeutics sponsors the most Age Related Macular Degeneration (ARMD) trials on record, review their full trial history before evaluating a specific study. See Stealth BioTherapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Age Related Macular Degeneration (ARMD) condition card totals 2 registered trials; most-linked intervention Placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.